{"nctId":"NCT02338960","briefTitle":"2. Study to Evaluate the Efficacy/Safety of Bremelanotide in Premenopausal Women With Hypoactive Sexual Desire Disorder","startDateStruct":{"date":"2015-01"},"conditions":["Hypoactive Sexual Desire Disorder"],"count":714,"armGroups":[{"label":"Bremelanotide (BMT/BMT)","type":"EXPERIMENTAL","interventionNames":["Drug: Bremelanotide"]},{"label":"Placebo (PBO/BMT)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Bremelanotide","Drug: Placebo"]}],"interventions":[{"name":"Bremelanotide","otherNames":["BMT","PT-141"]},{"name":"Placebo","otherNames":["PBO"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Has met diagnostic criteria for HSDD for at least 6 months\n* Is willing and able to understand and comply with all study requirements\n* Has a normal pelvic examination at screening\n\nMain Exclusion Criteria:\n\n* Subjects should be generally healthy premenopausal females with no psychological, gynecological or urological conditions which might contribute to the sexual dysfunction, compromise study participation, or confound interpretation of the study results\n* Not currently under treatment for the sexual dysfunction and willing to forego other treatments through the course of the clinical trial","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Efficacy of a Fixed Dose of Bremelanotide as Measured by FSFI (Question Q1 and Q2), 28-day Recall.","description":"As measured by change from baseline to end-of-study in the desire domain from the FSFI (Question Q1 and Q2), 28-day recall, co-primary endpoint - FSFI desire domain\n\nThis score is on a scale ranging from 1.2 to 6. A higher score on this scale represent an increase in sexual desire and is a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.63","spread":"1.036"},{"groupId":"OG001","value":"0.21","spread":"0.922"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.25","spread":"1.158"},{"groupId":"OG001","value":"0.70","spread":"1.220"}]}]}]},{"type":"PRIMARY","title":"Efficacy of a Fixed Dose of Bremelanotide as Measured by FSDS-DAO (Item 13)","description":"As measured by the change from baseline to End-of-Study of the Core Study in the bothered by low desire item from the FSDS-DAO (item 13).\n\nResponses range from 0 (never) to 4 (always). Lower scores on this scale represent an increase in sexual desire and indicate a better outcome.\n\nHigher scores indicate a worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.71","spread":"1.145"},{"groupId":"OG001","value":"-0.42","spread":"1.047"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"1.20"},{"groupId":"OG001","value":"-0.9","spread":"1.07"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study (EOS) in the Number of Satisfying Sexual Events (SSEs) Associated With Study Drug Administration","description":"Mean change from Baseline to end of study (EOS) in the number of satisfying sexual events (SSEs) that occurred within 16 hours of study drug dosing and reported within 72 hours. An increase in number indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.34"},{"groupId":"OG001","value":"0.0","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.19","spread":"1.997"},{"groupId":"OG001","value":"-0.31","spread":"1.296"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in Mean Desire Score (Q3) From the FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores on this scale range from 0 (no desire) to 3 (high desire). Scale is derived from a questionnaire (mean desire score) where an increase in value indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.065"},{"groupId":"OG001","value":"0.01","spread":"0.928"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"1.095"},{"groupId":"OG001","value":"0.33","spread":"1.023"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in Mean Satisfaction With Desire Score (Q4) From FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (no desire) to 3 (high desire). Scale is derived from a questionnaire (mean desire score) where a higher score indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.27","spread":"1.077"},{"groupId":"OG001","value":"0.11","spread":"0.977"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.76","spread":"1.127"},{"groupId":"OG001","value":"0.47","spread":"1.075"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the FSDS-DAO Total Score","description":"FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm. The FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. All responses are on a scale ranging from 0 (\"never\") to 4 (\"always\").\n\nTotal Scores range from 0 (never feel bothered) to 60 (always feel bothered). Decreased scores indicate improvement. A higher score on this scale indicates a worse outcome. The score is the mean change from Baseline observed at EOS (Baseline score - EOS score)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-9.7","spread":"13.79"},{"groupId":"OG001","value":"-5.6","spread":"12.06"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-18.4","spread":"14.06"},{"groupId":"OG001","value":"-11.1","spread":"14.37"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the FSFI Total Score","description":"Female Sexual Function Index (FSFI) The score is computed programmatically \\] resulting in a score on a scale ranging from 1.2 to 6 (Note: OLE: Open-label extension. Scores range from 2 to 36. An improvement in total FSFI score is an increase from baseline. A higher score on this scale represents an increase in sexual desire and is a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.45","spread":"7.383"},{"groupId":"OG001","value":"0.84","spread":"5.879"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"5.15","spread":"7.301"},{"groupId":"OG001","value":"3.14","spread":"7.281"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Mean Level of Sexual Arousal (Q6) From the FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores on this scale range from 0 (no desire) to 3 (high desire) Scale is derived from a questionnaire (mean desire score) where a higher score indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.04","spread":"1.068"},{"groupId":"OG001","value":"-0.01","spread":"0.906"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.33","spread":"0.987"},{"groupId":"OG001","value":"0.35","spread":"0.994"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Mean Satisfaction With Sexual Arousal (Q7) From the FSEP-R","description":"FSEP-R=Female Sexual Encounter Profile - Revised Scores range from 0 (no desire) to 3 (high desire) Scale is derived from a questionnaire (mean desire score) where a higher score indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.23","spread":"1.112"},{"groupId":"OG001","value":"0.09","spread":"0.974"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.60","spread":"1.107"},{"groupId":"OG001","value":"0.47","spread":"1.102"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Scored Time Spent Being Concerned by Difficulty With Sexual Arousal (Q14) From the FSDS-DAO","description":"FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm.\n\nThe FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. Scores on this scale range from 0 (\"never\") to 4 (\"always\"). Decreased scores indicate improvement.\n\nA higher score on this scale indicates a worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.23"},{"groupId":"OG001","value":"-0.4","spread":"1.11"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.3","spread":"1.11"},{"groupId":"OG001","value":"-0.9","spread":"1.17"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Arousal Domain of the FSFI (Q3 to Q6)","description":"Female Sexual Function Index (FSFI)\n\nThe score is computed programmatically using the algorithm described by Rosen, resulting in a score ranging from 1.2 to 6. Higher scores on this scale represent an increase in sexual desire and is a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.52","spread":"1.535"},{"groupId":"OG001","value":"0.18","spread":"1.254"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.19","spread":"1.560"},{"groupId":"OG001","value":"0.83","spread":"1.563"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Total Number of SSEs","description":"Change from Baseline to EOS in the total number of satisfying sexual events SSEs. A higher number of events indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":"1.34"},{"groupId":"OG001","value":"-0.0","spread":"1.20"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.25","spread":"2.376"},{"groupId":"OG001","value":"-0.35","spread":"1.655"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Desire Domain of the FSFI (Q1 to Q2) Throughout the Entirety of the Double-blind Phase","description":"FSFI = Female Sexual Function Index\n\nThe score is on a scale ranging from 1.2 to 6. A higher score on this scale represents an increase in sexual desire and is a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.78","spread":"1.052"},{"groupId":"OG001","value":"0.16","spread":"0.909"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Score for Feeling Bothered by Low Sexual Desire as Measured by the FSDS-DAO (Item 13) Throughout the Entirety of the Double-blind Phase","description":"FSDS-DAO = Female Sexual Distress Scale - Desire/Arousal/Orgasm.\n\nThe FSDS-DAO is a validated 15-item self-assessment of sexual feelings and problems. The score is on a scale ranging from 0 (\"never\") to 4 (\"always\"). Decreased scores indicate improvement. A higher score indicates a worse outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.8","spread":"1.22"},{"groupId":"OG001","value":"-0.4","spread":"1.02"}]}]}]},{"type":"SECONDARY","title":"Efficacy of a Fixed Dose of Bremelanotide, as Measured by the Change in Baseline to End of Study in the Number of SSEs Associated With Study Drug Administration Throughout the Entirety of the Double-blind Phase","description":"Mean change from Baseline to EOS in the number of satisfying sexual events SSEs associated with study drug administration throughout the entirety of the double-blind phase. A higher number of events indicates a better outcome.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.1","spread":"1.37"},{"groupId":"OG001","value":"-0.1","spread":"1.28"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":303},"commonTop":["Nausea","Flushing","Sunburn","Headache","Injection site pain"]}}}